Pitch Deck



Presented by Maria Burian, M.D., Ph.D., M.B.A. Founder and Consultant



Website: www.igenepharma.com

E-mail: info@igenepharma.com

Podcast: https://substack.com/@igenepharma



Your Individual Path to Better Treatment Choice

Introduction


With a unique blend of scientific expertise and innovation, iGenePharma delivers comprehensive solutions in Personalized Medicine, powered by artificial intelligence, genomic insights, and digital health technologies to enable optimal drug prescriptions und usage.

Our mission is to advance education and practice in Personalized Medicine while providing point-of-care monitoring tools that optimize therapeutic outcomes and enhance patient care.

Our vision is to empower clinicians and patients alike — transforming treatment from reactive to proactive, and from generalized to genuinely personalized.



iGenePharma



Problems

FDA has approved over 23000 different prescription drugs for marketing (FDA, 2024). The percentage of patients who have at least one drug-related problem (DRP) while in care is often quite high, frequently falling in the 50% to 85% range, particularly in complex or older patient populations (like those with polypharmacy).

High Failure Rates in Drug Use

More than 39 Million around the world have drug use disorders (United Nations 2023).

➤ Limited Understanding of Drug Responses

Not all patients respond similarly to drugs. Genetic variations complicate treatment plans.

Insufficient Personalized Treatment Options Available

A one-size-fits-all approach is inadequate. Current models fails to tailor reccomendations. Insufficient understanding of the therapeutic journey by patients. Lack of monitoring options.



Solutions

By combining four innovative solutions iGenePharma aims to address unmet needs in patients with drug-related problems (DRP), such as substance misuse and adverse drug events.



* Artifical intelligence

Harnessing the power of AI to make personalized medicine a practical reality — ensuring that every patient receives the right treatment, at the right time, and at the right dose.



Pharmacogenetic tests

Utilizing individual genomic insights to provide tailored treatment strategies that enhance therapetic outcome for patients on drug treatment.



Immersive education

Understaning the concepts of Personalized Medicine by patients, caregivers and medical personal who want to follow the path of best therapeutic choice.



Point of care monitoring

Utilizing digital health technologies to monitor and support adaptive patients-specific treatment pathways at patient bedside - or even at the patient's home reducing unnecessary interventions and healthcare costs.



Personalized Medicine

Artificial Intelligence +37%


Digital Health +12%

In Vitro Diagnostics +7%

"Healthcare-AI" segment worldwide is expected to grow at ~ 37% CAGR in 2025-2034.

Global Digital Health Market is expected to grow at ~ 12% CAGR in 2025-2034.

Worldwide IVD market is expected to grow at ~7% CAGR in 2025-2034.




Sources: GlobeNewswire, Precedence Research



Prescription Drugs Market


Prescription Drug Market
+6%

- Prescription drug market continues to grow worldwide at predicted ~6% CAGR in 2025-2034.
- Total number of prescriptions per year reaches 13 drugs in patients age 50 to 64 and 22 drugs in patients age 80 (US data).



Source: Precedence Research

If drug prescription/usage go wrong...



Research highlights that a significant portion of Drug-Related Problems (sometimes over 50%) are considered avoidable or preventable.





iGenePharma brings innovation to the point of care—combining artificial Intelligence, real-world health digital data, and in-vitro-diagnostics to guide and monitor optimal treatment decisions.

DISCOVER OUR SERVICES AND PRODUCTS

PERSONALIZED MEDICINE AI



We create an artificial intelligence platform to expand personalized medicine from academic knowledge to innovative utilty tool.

PERSONALIZED MEDICINE LAB




We set up an up-to date lab facility to develop genomic tests (IVID) to determine established gene-drug pairs from patient biomaterials to guide better drug prescription.

EDUCATIONAL PLATFORM



We develop learning strategies to give insights about therapeutic journey and to educate how to follow the path of best therapeutic choice.

PERSONALIZED POINT OF CARE DEVICE



We partner with digital health companies to co-develop a point of care smart device to monitor and safeguard patient's best choice in drug treatment.



Al in Personalized Medicine



ALINTIELLIGENCE FOR SMARTER CLINICAL DECISIONS

Drug prescription entries


Curated databank with established gene-drug pairs, drug-drug interactions and drug contraindications

potential platform for new drug discoveries

PharmaMind will optimize drug prescription

Smart Lab for Personalized Medicine






iGenePharma will advice on better drug prescription based on individual genetic profile

Understanding your Therapeutic Journey

Concepts of Personalized Medicine





iGenePharma will provide education for medical personal and patients to guide better therapeutic path

Point of Care Drug Prescription Monitoring



Wearabale sensors, genomic data, drug prescriptions, tele-health consultations

Integration of genomic tests, real-world digital health data, tele-health consultations and drug prescriptions

iGenePharma will monitor and safeguard drug therapies to assure best therapeutic outcomes using secure, cloud-based analytic platform



Competitive Advantage

Unique Value Proposition

Niche

Focused exclusively on Al-driven Personalized Medicine — integrating pharmacogenetics, digital health, and real-world prescription data to optimize therapeutic outcomes.

Our specialization enables deep domain knowledge and targeted innovation unmatched by broader health-tech competitors.

Easy

Our modular, cloud-based analytic platform seamlessly integrates with clinical systems, EHRs, and laboratory workflows, reducing implementation time and complexity.

We enable healthcare providers and pharma partners to adopt Al-driven insights without infrastructure disruption.

Agile

Lean and flexible operations allow us to respond rapidly to emerging technologies and market needs.

Through agile development and crosssector partnerships, iGenePharma continuously evolves — staying ahead of both technological and regulatory trends.



DIRECT COMPETITORS

- 1. Tempus AI (USA)
- 2. Owkin (France / US)
- 3. Sophia Genetics (Switzerland/US/Global)
- 4. GenXys Health (Canada)
- 5. PromicsEdge (global)
- 6. Roche Diagnostics (Switzerland/US/Global)
- 7. ADA Health (global)


INDIRECT COMPETITORS

- 1. Electronic Health Records / Health IT platforms (Epic, MediData)
- 2. Clinical Decision Support Startups (ADA Health, Intermedica)
- 3. Diagnostic & Biotechfirms (Roche Diagnostics, Foundation Medicine)



Competitive Positioning

Clinical integration strongest



Clinical integration weakest

ada



Our Super Team

iGenePharma includes partners with strong expertise in Personalized Medicine, AI, IVID and Digital Health. Our team is positioned to become a trusted enabler in the personalized medicine ecosystem.





Artificial Intelligence (PARTNER)

(PARTNER)

Immersive Education

TBD

IVID (PARTNER) TBD

Digital Health (PARTNER)



Thank You!

We are here to turn complex data into intelligent solutions that improve therapy choices and patient well-being.